FDA Warns of Rare but Serious Drug Reaction

December 4, 2023
The Dup15q Alliance is aware of the recent release by the FDA regarding Keppra, Keppra XR, Elepsia XR, Spritam (levetiracetam) and Onfi, Sympazan (clobazam) warning about the risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). This adverse event is rare and generally occurs 2-8 weeks after starting a medication. We urge anyone with concerns about their medications to discuss with their prescribing provider. The FDA recommends not stopping these medications without discussing with your health care provider, as stopping these medications suddenly can lead to uncontrolled seizures.
FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan) | FDA

Related Posts

Recall – Vigabatrin for Oral Solution USP

Recall – Vigabatrin for Oral Solution USP

TOPIC: Vigabatrin for Oral Solution USP, 500 mg by InvaGen Pharmaceuticals: Recall - Due to Leaking Sachets AUDIENCE: Patient, Health Professional, Pharmacy, Pediatric, Neurology ISSUE: InvaGen Pharmaceuticals is recalling one lot, NB301030, of Vigabatrin for Oral...

Medication Recall Alert Sabril® (Vigabatrin)

Medication Recall Alert Sabril® (Vigabatrin)

Our friends at the Epielpsy Foundation have shared the Following Medication Recall The company that makes Sabril® (vigabatrin) for oral solution, a prescription medication to manage seizures in children and adults, has announced a recall of this medication because of...

MEDICATION ALERT – FELBAMATE (Generic)

MEDICATION ALERT – FELBAMATE (Generic)

We understand that some families in our community may be having challenges getting prescriptions filled for generic Felbamate oral suspension and tablets. If you need assistance with obtaining your medication, contact our 24/7 Helpline at 1-800-332-1000 for connection...